RNAi-Based Approaches for Pancreatic Cancer Therapy

Pancreatic cancer is one of the most lethal forms of cancer, predicted to be the second leading cause of cancer-associated death by 2025. Despite intensive research for effective treatment strategies and novel anticancer drugs over the past decade, the overall patient survival rate remains low. RNA...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2021-10, Vol.13 (10), p.1638
Main Authors: Kim, Min Ju, Chang, Hyeyoun, Nam, Gihoon, Ko, Youngji, Kim, Sun Hwa, Roberts, Thomas M., Ryu, Ju Hee
Format: Article
Language:English
Subjects:
Binding sites
Cancer therapies
Chemotherapy
FDA approval
Gene expression
Market entry
Metastasis
miRNA
Mutation
nanocarrier
Pancreatic cancer
Protein expression
Proteins
Review
RNA interference
siRNA
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic cancer is one of the most lethal forms of cancer, predicted to be the second leading cause of cancer-associated death by 2025. Despite intensive research for effective treatment strategies and novel anticancer drugs over the past decade, the overall patient survival rate remains low. RNA interference (RNAi) is capable of interfering with expression of specific genes and has emerged as a promising approach for pancreatic cancer because genetic aberrations and dysregulated signaling are the drivers for tumor formation and the stromal barrier to conventional therapy. Despite its therapeutic potential, RNA-based drugs have remaining hurdles such as poor tumor delivery and susceptibility to serum degradation, which could be overcome with the incorporation of nanocarriers for clinical applications. Here we summarize the use of small interfering RNA (siRNA) and microRNA (miRNA) in pancreatic cancer therapy in preclinical reports with approaches for targeting either the tumor or tumor microenvironment (TME) using various types of nanocarriers. In these studies, inhibition of oncogene expression and induction of a tumor suppressive response in cancer cells and surrounding immune cells in TME exhibited a strong anticancer effect in pancreatic cancer models. The review discusses the remaining challenges and prospective strategies suggesting the potential of RNAi-based therapeutics for pancreatic cancer.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics13101638